Video

Dr. Eng Discusses the ADORE Trial in Rectal Cancer

Author(s):

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

The ADORE trial looked at the role of adjuvant chemotherapy based on a patient’s pathologic postoperative staging. In the trial, adjuvant oxaliplatin was added to leucovorin and 5-fluorouracil (5-FU; FOLFOX) and compared with leucovorin/5-FU alone. Researchers validated that there is an improvement in disease-free survival (DFS) for patients with stage III disease receiving FOLFOX, says Eng. This trial was done in patients with locally advanced rectal cancer.

The study met its primary endpoint of DFS, suggesting a clear benefit with the addition of oxaliplatin. Adjuvant chemotherapy remains a controversial topic in rectal cancer though, Eng says. The data from ADORE have been the most positive findings to date in support of adjuvant chemotherapy.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO